Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis.

ABSTRACT:

Introduction

This systematic review and meta-analysis aimed to assess the prognostic value of testosterone in patients with castration-resistant prostate cancer (CRPC).

Materials and methods

PubMed, Web of Science, and Scopus databases were systematically searched until December 2019, according to the Preferred Reporting Items for Systemic Review and Meta-analysis statement. The endpoints were progression-free survival (PFS) and overall survival (OS).

Results

We identified 11 articles with 4206 patients for systematic review and nine articles with 4136 patients for meta-analysis. Higher testosterone levels were significantly associated with better OS (pooled HR 0.74, 95% CI 0.58-0.95) and better PFS (pooled HR 0.51, 95% CI 0.30-0.87). Subgroup analyses based on the tr

SUBMITTER: Miura N 

PROVIDER: S-EPMC7572350 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature